![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
| Item Type: | Letter |
|---|---|
| Title: | Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the 2 GHSG NIVAHL trial |
| Creators: |
Robertz, Anne Sophie, Bühnen, Ina, Meissner, Julia, Trautmann-Grill, Karolin, Herhaus, Peter, Halbsguth, Teresa, Schaub, Valdete, Kerkhoff, Andrea, Mathas, Stephan  ORCID: https://orcid.org/0000-0001-9626-1413, Bormann, Matthias, Dickhut, Andreas ORCID: https://orcid.org/0009-0008-9794-9875, Jaworek, Christian P. ORCID: https://orcid.org/0009-0007-9338-2624, Fuchs, Michael, Kobe, Carsten ORCID: https://orcid.org/0000-0002-2909-0826, Baues, Christian ORCID: https://orcid.org/0000-0003-1733-6064, Borchmann, Peter, von Tresckow, Bastian ORCID: https://orcid.org/0000-0003-1410-4487, Behringer, Karolin ORCID: https://orcid.org/0000-0002-7035-1784 and Bröckelmann, Paul J. ORCID: https://orcid.org/0000-0001-9662-9900
|
| Abstract: | In 82 patients with classic Hodgkin lymphoma, stable gonadal hormone levels were observed up to 24 months after nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) first-line treatment. These findings suggest preserved gonadal function and fertility after 4×N-AVD. The trial was registered at www.clinicaltrials.gov as NCT03004833. |
| Keywords: | Antineoplastic Combined Chemotherapy Protocols, Dacarbazine, Doxorubicin, Fertility, Hodgkin Disease, Nivolumab, Vinblastine, Young Adult |
| Source: | Blood |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology / Elsevier |
| Volume: | 147 |
| Number: | 25 |
| Page Range: | 3118-3121 |
| Date: | 18 June 2026 |
| Official Publication: | https://doi.org/10.1182/blood.2025031809 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
